Medical Device Definition in Myanmar

1. Key takeaways

Myanmar’s definition of a medical device adopts the AMDD text directly: it covers any instrument, apparatus, implement, machine, appliance, implant, in vitro reagent and calibrator, software, material or other similar or related article intended by the product owner to be used, alone or in combination, for human beings for one of seven specific intended purposes; and its primary intended action is not achieved by pharmacological, immunological or metabolic means in or on the human body, although it may be assisted in its function by such means.

• The definition contains two constituent elements: a positive list of seven intended purposes and a negative exclusion for products whose primary action is pharmacological, immunological or metabolic.
• For borderline products such as drug-eluting stents and drug-loaded dressings, both elements must be tested at the same time.
• The definition structure can be recorded as: 2 constituent elements, a positive list of 7 intended purposes, and 1 exclusion criterion.
• Software is expressly included in the definition, so software as a medical device (SaMD) is regulated as a device in Myanmar and does not follow the drug pathway.
• The source of the definition is Section 1, Definition of Medical Device, of the Technical Guideline for Online Submission of Medical Devices of the Myanmar FDA.

2. Legal basis

The table below reproduces the definitional framework as set out in the FDA technical guideline. Because Myanmar has no dedicated device statute, this administrative document is the operative source of the definition, and its wording tracks the AMDD so closely that regional determinations can be reused as supporting evidence.

3. Expert insights

Insight 1: the first anchor of the definition is the intention of the product owner, not objective performance. The wording uses intended by the product owner. This means that the intended purpose declared by the manufacturer in the instructions for use and labelling is the primary basis for determining the nature of the product. A drafting error in the instructions for use can directly change the statutory classification of the product.

Insight 2: the seven intended purposes form a closed list. To determine whether a product falls within the device definition, companies must check whether its intended purpose can be placed under one of items (a) to (g). This list is fully consistent with the AMDD, which makes it convenient to reuse determinations made in other ASEAN markets as supporting arguments.

Insight 3: the exclusion criterion applies a primary mode of action test. The provision does not require the product to be entirely free of pharmacological ingredients; it requires that the primary intended action is not achieved by pharmacological, immunological or metabolic means. Combination products such as drug-eluting stents and antibiotic-loaded bone cement require a case-by-case argument on the primary mode of action, documented in writing in the technical file.

Insight 4: software is expressly brought within the device scope. The enumeration of articles includes software, which operates together with item (g) on the provision of information by in vitro examination. Standalone software (SaMD) is therefore managed as a device in Myanmar and does not follow the drug pathway or a general software pathway.

Insight 5: the uniformity of the definition lowers cross-market conversion costs. Because Myanmar adopts the AMDD definition consistent with the rest of ASEAN, companies can reuse the definitional arguments already completed in other ASEAN markets, but they must still submit the declaration texts in the formats required by the Myanmar FDA. The reuse of regional arguments is a practical estimate pending verification against the FDA’s current review practice.

4. Practical recommendations

• Express the intended purpose carefully in the instructions for use and labelling. The content of the declaration directly determines the classification of the product.
• Complete the primary mode of action argument for combination products in advance. Prepare a written argument and include it in the technical documentation.
• Manage standalone software along the device pathway. Do not conflate it with the drug pathway or a general software pathway.
• Reuse definitional conclusions from other ASEAN markets as supporting material. Attach the declaration documents in the Myanmar format.
• Reassess the classification before changing the intended purpose. A change of purpose may trigger re-registration.

5. Verification checklist

• □ Confirmed that the definition comes from Section 1 of the Technical Guideline for Online Submission of Medical Devices
• □ Confirmed that the scope of articles includes software and in vitro reagents
• □ Checked the list of seven intended purposes
• □ Understood that the exclusion criterion applies a primary mode of action test
• □ Expressed the intended purpose carefully in the instructions for use
• □ Completed a written primary mode of action argument for combination products
• □ Managed standalone software along the device pathway

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com